Stock of the Day

September 19, 2022

Sanofi (SNY)

$40.61
+$0.32 (+0.8%)
Market Cap: $98.46B

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi Bull Case

Here are some ways that investors could benefit from investing in Sanofi:

  • Sanofi recently expanded its global alliance with Regeneron in a deal valued at up to $8 billion, which includes a $1 billion upfront payment and adds four next-generation, long-acting antibodies to the pipeline that has already produced the blockbuster therapy Dupixent, providing a significant catalyst for future growth in type 2 inflammatory diseases.
  • The company is currently trading at $39.74, which is near its 52-week low of $39.18, offering a potential entry point for investors given that the consensus price target from analysts is $49.50, suggesting substantial upside potential relative to the current market price.
  • Sanofi offers a high dividend yield of 4.39%, which is attractive for income-focused investors, and the company recently raised its dividend by over 10%, demonstrating a commitment to returning capital to shareholders while maintaining a stable payout.
  • The stock exhibits a low beta of 0.33, indicating that it is less volatile than the broader market, which can provide a defensive characteristic for portfolios seeking stability during periods of market uncertainty or economic downturns.
  • Recent earnings data shows strong revenue growth, with the company reporting revenue of $13.36 billion in the last reported quarter, representing a 16.0% year-over-year increase, driven by momentum in new drugs like Altuviiio, Ayvakit, and Sarclisa that are poised to drive growth beyond its flagship product.

Sanofi Bear Case

Investors should be bearish about investing in Sanofi for these reasons:

  • The consensus rating from analysts is currently "Hold," with a recent downgrade by Wall Street Zen from "Buy" to "Hold" and a downgrade by Weiss Ratings to "Sell," reflecting a lack of strong bullish conviction among research firms despite the recent partnership news.
  • Short interest in Sanofi has been increasing, with shares shorted rising to over 10.6 million shares as of the most recent reporting period, indicating that a significant portion of the market is betting against the stock's future performance.
  • The company's price-to-earnings ratio of 20.81 is relatively high compared to some peers, and the PEG ratio of 1.21 suggests that the stock may be overvalued relative to its expected earnings growth, limiting the margin of safety for new investors.
  • Sanofi's balance sheet shows a current ratio of 0.99 and a quick ratio of 0.64, both below 1.0, which indicates that the company may face liquidity challenges in meeting its short-term obligations with its current assets, potentially signaling financial stress.
  • The stock has experienced a significant decline from its 52-week high of $52.68 to its current level, and it has hit new 12-month lows in recent months, suggesting persistent downward pressure and a lack of near-term catalysts to reverse the trend.

MarketBeat: Week in Review 8/15 - 8/19

Written By Chris Markoch on 8/20/2022

This week investors received more news that paints a mixed picture. Retail sales showed that consumers are making tradeoffs. And while that is signaling some relief at the gas pump, it’s not doing much for the outlook of retailers like Walmart (NYSE:WMT) and Target (NYSE:TGT). On the other hand there’s increasing evidence that layoffs are accelerating. This means that the markets will continue to be volatile in advance of clarity from the Federal Reserve. That won’t happen until September and there’s will be another wave of economic data between now and then. And you can count on MarketBeat to provide you with insights to help you navigate this volatility. Here are some of our most popular articles from this week.

Articles by Jea Yu

In volatile markets, it helps to keep things simple. That’s part of the advice Jea Yu gave to investors as part of our explainer series on how to invest in this volatile market. In fact, Yu shows our readers how they can put together a four-stock portfolio that feature companies with business models that make them exceptional recession hedges. One stock that wouldn’t qualify as a recession hedge is AMC Entertainment (NYSE:AMC). Nevertheless, this week many meme stocks were back in focus. And Yu explains the company’s announcement of a dividend in the form of AMC Preferred Equity (APE) units and what it means for the retail investors who have put their faith in the stock.  And just when you thought AdTech was dead, Yu points out that The Trade Desk (NYSE:TTD) just delivered an earnings report and outlook that shows why its programmatic advertising model may help AdTech to make a comeback.

Articles by Thomas Hughes

Second quarter earnings season is almost in the books. That means it’s time to sort out the winners and losers. As Thomas Hughes points out, one way to do that is to look at stocks that analysts are upgrading. And Hughes gives investors five of the stocks that are positioned for second half growth on the backs of analyst estimates. This week gave investors a look at the health of the retail sector. One area that continues to show strength is warehouse clubs. Hughes writes about the strong earnings report from BJ’s (NYSE:BJ) and what that may mean for Costco (NASDAQ:COST) when it reports next month. Hughes was also looking at the continued strength in blue-chip technology stocks, specifically that of Cisco Systems (NASDAQ:CSCO). The company continues to show why its products and services are essential to our connected world.  

Articles by Sam Quirke

Sam Quirke was writing about Micron Technologies (NASDAQ:MU) and why the beleaguered semiconductor stock may be ready for a comeback.  It appears that the industry may be shaking off the effects of supply chain disruptions and cost pressures due to inflation. Quirke lays out the fundamental drivers for the stock and why that case is being verified by technical indicators.

Articles by Chris Markoch

Apple (NASDAQ:AAPL) has been one of the big names leading the bear market rally. Some analysts are forecasting the stock may be on the verge of new highs. However, as Chris Markoch writes if that happens, it will be, in part, because of its attempt to take a leadership position in streaming live sports.  Markoch was also looking at the latest retail numbers and explaining why that may bode well for both Coca-Cola (NYSE:KO) and PepsiCo (NASDAQ:PEP) stocks. However, Markoch takes a more skeptical look at shares of Starbucks (NASDAQ:SBUX) and suggests the stock may face headwinds even as its consumers remain loyal.

Articles by Kate Stalter

Kate Stalter was also looking at the semiconductor sector as a possible turnaround story. Stalter makes the case for ON Semiconductor (NASDAQ:ON) stock which is up 26.11% in the past month and 28.21% in the past three months. Cybersecurity stocks are also starting to turn higher as earnings reports show that demand for these products remains strong and sticky. And Stalter analyzes CrowdStrike (NASDAQ:CRWD) as one of the leaders in this space. The risk/reward potential of pharmaceutical stocks also got put in focus this week with news that Sanofi (NASDAQ:SNY) was ending two studies of its breast cancer treatment candidate, amcenestrant. SNY stock shares dropped sharply, but Stalter explains why investors who have time on their side may not want to give up on the stock just yet.

← Previous Stock of the DayNext Stock of the Day →

Recent News